In September 2013, a 69-year-old Caucasian man who was anti--JC virus (JCV) antibody positive was admitted to our hospital with slowly progressing right hemiparesis and aphasia lasting for approximately 6 months. Medical history revealed arterial hypertension, biological aortic valve replacement, and psoriasis vulgaris, treated with 3--6 tablets daily of dimethylfumarate (DMF; 120 mg)/ethylhydrogenfumarate (EHF; 95 mg) (Fumaderm, Biogen Idec, Ismaning, Germany) since December 2008 (table e-1 at [Neurology.org/nn](http://Neurology.org/nn)). No other immunosuppressive pretreatment had been given. In April/May 2013, the patient recognized a steadily progressing weakness of the right leg. In June 2013, an external diagnosis of ischemic stroke was made. An MRI scan (figure e-1), which was performed after deterioration of clinical symptoms, revealed a subcortical left hemispheric lesion; biopsy demonstrated macrophage-dominated inflammation, dysmorphic astrocytes, simian virus 40 positivity, and several p53- and MiB1-positive cells, suggestive of a JCV encephalitis (figure e-2). JCV DNA was detected in CSF at 2 different time points using a highly sensitive PCR protocol (September 24, 2013, 16 copies/mL; October 7, 2013, 42 copies/mL),^[@R1]^ leading to the diagnosis of progressive multifocal leukoencephalopathy (PML) in September 2013. Further diagnostic workup (table e-2) unmasked toxic bone marrow damage (figure e-3) and an increased excretion of kappa light chains in urine without any evidence for a plasmocytoma. Taking into account the patient\'s initial presentation with a slowly progressive paresis since April/May 2013 as well as the initial MRI scan (figure e-1), which is compatible with the PML diagnosis, we believe that the onset of PML was in April/May without preexisting leukopenia and only moderate lymphopenia (grade 2 lymphopenia: 724--738 cells/µL, [figure](#F1){ref-type="fig"}). Several weeks later, white blood cell count dropped to a minimum of 4,800 cells/µL with 288 cells/µL lymphocytes under continuous Fumaderm treatment. Fumaderm was discontinued, and treatment with mirtazapine (45 mg/day; Remergil, MSD Sharp und Dohme GmbH, Haar, Germany), mefloquine (250 mg/week; Lariam, Roche Pharma AG, Grenzach-Wyhlen, Germany), and levetiracetam (1,000 mg/day; Keppra, UCB Pharma GmbH, Monheim, Germany) was initiated.^[@R2]^
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One month later, a mild immune reconstitution inflammatory syndrome (IRIS) occurred, with deterioration of the hemiparesis (Karnofsky index \[KI\] 50%) accompanied by gadolinium enhancement on MRI. Two IV methylprednisolone treatments (each 500 mg/day for 3 days) were given. In June 2014, hemiparesis and aphasia had improved (KI 90%), JCV CSF PCR was negative, and leukocyte and lymphocyte counts had normalized (8,310 cells/µL and 1,240 cells/µL, respectively). Cerebral MRI scan was stable.

In contrast to the previously described cases of Fumaderm- and Psorinovo-associated PML in psoriasis,^[@R3],[@R4]^ we present a case without a preexisting, long-standing, and severe leukopenia/lymphopenia ([figure 1](#F1){ref-type="fig"}) or immunosuppressive pretreatment. In the absence of other discernable myelotoxic factors, bone marrow damage might have been related to Fumaderm treatment. Despite the diagnostic delay, disease course, including IRIS, was mild.^[@R3][@R4][@R5]^ Further studies on potential myelotoxic effects of fumarates and specific effects of DMF vs EHF are warranted. Physicians treating multiple sclerosis patients with DMF should be vigilant for PML as a possible but rare side effect. A long-lasting and presumably severe lymphopenia may especially predispose patients to PML.
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